MedTrace Logo

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

NCT01490086 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 234

Last updated 2025-08-08

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.

Conditions

  • Acute Schizophrenia
  • Schizoaffective Disorder

Interventions

DRUG

RP5063

daily

DRUG

placebo

daily

DRUG

aripiprazole

daily

Sponsors & Collaborators

  • Reviva Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • M Cantillon · Fundacion REVIVA, Red de VIH del Valle del Cauca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • United States
  • India
  • Malaysia
  • Moldova
  • Philippines

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01490086 on ClinicalTrials.gov